摘要
目的:探讨儿脾醒颗粒治疗功能性消化不良(Functional dyspepsia,FD)患儿的临床疗效。方法:回顾性分析2021年3月至2022年3月期间在郑州大学附属儿童医院收治的90例FD患儿的临床资料,按照不同治疗方案将其分为治疗组和对照组,每组各45例。对照组患儿采用常规治疗方案,治疗组患儿在对照组基础上给予口服儿脾醒颗粒。观察两组临床疗效、治疗前后疾病功能性消化不良生存质量量表(Functional digestive disorders quality of life questionnaire,FDDQL)和整体症状量表(Global overall symptom scale,GOSS)评分、血清胃肠激素和脑肠肽水平、以及不良反应发生率。结果:治疗两周后,治疗组在腹胀、嗳气、腹痛、纳差等症状发生率明显低于对照组,临床疗效明显高于对照组(P<0.05)。治疗组GOSS评分、生长抑素(Somatostatin,SS)、血管活性肠肽(Vasoactive intestinal peptide,VIP)显著低于对照组(P<0.001)。治疗组FDDQL评分、胃动素(Motilin,MTL)、神经肽Y(Neuropeptide Y,NPY)显著高于对照组(P<0.001)。两组患儿不良反应发生率无明显差异(P>0.05)。结论:儿脾醒颗粒治疗儿童FD临床效果好,且安全性高,值得临床上推广应用。
Objective:To investigate the clinical efficacy of Erpixing Keli in children with functional dyspepsia(FD).Methods:The clinical data of 90 children with FD were treated at the Affiliated Children's Hospital of Zhengzhou University from March 2021 to March 2022.They were divided into treatment group and control group according to different treatment plans,with 45 cases each.The children in control group was adopted the conventional treatment regimen,and the children in treatment group was added oral Erpixing Keli.The pre-and post-treatment clinical efficacy,functional digestive disorders quality of life questionnaire(FDDQL),global overall symptom scale(GOSS)score,serum gastrointestinal hormone and brain-intestinal peptide levels,and the incidence of adverse reactions were observed.Results:The incidence of abdominal distension,belching,abdominal pain and poor tolerance in the treatment group was significantly less than that of the control group,and the clinical efficacy of the treatment group was higher than the control group(P<0.05).Compared with the control group,in the treatment group GOSS score,somatostatin(SS),and vasoactive intestinal peptide(VIP)were significantly lower(P<0.001).FDDQL score,motilin(MTL),and neuropeptide Y(NPY)were significantly higher(P<0.001).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Erpixing Keli in the treatment of FD in children has good clinical effect and high safety,which is worthy of clinical promotion and application.
作者
秦凌云
严海燕
王跃生
杨英
薛福敏
张敬
李小芹
Qin Ling-yun;Yan Hai-yan;Wang Yue-sheng;Yang Ying;Xue Fu-min;Zhang Jing;Li Xiao-qin(Department of Gastroenterology,The Affiliated Children's Hospital of Zhengzhou University,Henan Children's Hospital,Zhengzhou Children's Hospital,Zhengzhou 450000,China)
出处
《四川生理科学杂志》
2024年第1期5-8,共4页
Sichuan Journal of Physiological Sciences
基金
河南省二〇二一年科技发展计划(212102310037)。
